May 20, 2015
12:00 pm to 1 pm EDT

Sponsored by

Webinar Description:

Loss-of-function genetic screens with pooled sgRNA and shRNA libraries aid in discovery / prioritization of drug targets, understanding of disease progression and gene-disease associations, analysis of signal transduction pathways, characterization of the mechanisms for compounds, uncovering of synergistic gene interactions, and identification of markers of drug resistance and sensitivity. This webinar presents a comparison of loss-of-function genetic screens performed with CRISPR versus RNAi technology.

Learning Objectives:

  • Understand the molecular biology behind RNAi versus CRISPR mechanism of action
  • Identify the benefits of loss-of-function screens with pooled lentiviral libraries
  • Design screening protocols relevant to the hypothesis being studied
  • Choose an effective loss-of-function genetic screening system to best fit the scientific question
  • Design effective validation experiments using RNAi or CRISPR

Who should attend:

  • Oncology / Cancer Biology Researchers
  • Infectious Diseases / Inflammation Researchers
  • Researchers looking to identify novel drug targets
  • Researchers looking for genetic sensitivities to overcome drug resistance
  • Next-Gen Sequencing Users


Paul DiehlPaul Diehl, Ph.D.

Director of Business Development

Cellecta, Inc.

Dr. Paul Diehl received his Ph.D. in Biochemistry from Washington State University in 1993. Over the past 20 years, he has been involved in developing, launching, and supporting a range of products for genetic analysis and cell biology in various positions at companies such as B-Bridge International, Arcturus Bioscience, Agilent Laboratories, Display Systems Biotech, and Clontech Laboratories. Currently, he helps organize Cellecta's efforts at developing and utilizing new approaches for genome-wide functional analysis as the company's Director of Business Development.


Karim Hyder

Director of Operations

Cellecta, Inc.